ArticleTherapeutic advances in musculoskeletal disease2012
Treatment and management of pseudogout: insights for the clinician.
Article in Therapeutic advances in musculoskeletal disease, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 73 citations in OpenAlex.
- Serum β-hydroxybutyrate as a diagnostic biomarker distinguishing acute calcium pyrophosphate crystal arthritis from rheumatoid arthritis.Clinical rheumatology · 2026Article
- Article
- A Case of Pseudogout in an Adolescent on Isotretinoin.Case reports in rheumatology · 2026Article
- Article
- Article
- An Update on the Diagnosis and Management of Calcium Crystal Disease.Current rheumatology reports · 2023Review
- Atypical Presentation of Gout: A Case Report.Cureus · 2023Article
- Article
- Diagnosis and Treatment of Calcium Pyrophosphate Deposition (CPPD) Disease: A Review.Open access rheumatology : research and reviews · 2023Review
- Orthopaedic Management of Gout.Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews · 2022Article
- Activation and Function of NLRP3 Inflammasome in Bone and Joint-Related Diseases.International journal of molecular sciences · 2022Review
- Intercostal Muscle Abscesses in Infective Endocarditis Associated With Migratory Deposition of Calcium Pyrophosphate.Cureus · 2022Article
- Synovial fluid analysis for the enhanced clinical diagnosis of crystal arthropathies in a tertiary care institution.Clinical rheumatology · 2021Article
- Tophaceous pseudogout in a 12-year-old dog, with a review of applicable laboratory tests.Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc · 2020Article
- Introducing variability in targeting the microtubules: Review of current mechanisms and future directions in colchicine therapy.Pharmacology research & perspectives · 2020Review
- Interleukin-1 Blockade in Polygenic Autoinflammatory Disorders: Where Are We now?Frontiers in pharmacology · 2020Review
- Clinical Presentation, Management, and Prognosis of Pseudogout in Joint Arthroplasty: A Retrospective Cohort Study.Journal of bone and joint infection · 2019Article
- Calcium crystal deposition diseases - beyond gout.Nature reviews. Rheumatology · 2018Review
- Cartilage diseases.Matrix biology : journal of the International Society for Matrix Biology · 2018Review
- Severe calcium pyrophosphate dihydrate deposition disease of the metacarpophalangeal joints.BMJ case reports · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pseudogout and the associated calcium pyrophosphate dihydrate (CPPD)- crystal-related arthropathies are common conditions that present particular management problems in clinical practice as they often affect older patients with multiple medical comorbidities. The epidemiology, metabolic and endocrine disease associations, and routine investigations used in the diagnostic workup are briefly reviewed. Current treatment approaches that are mainly directed at relieving the symptoms of joint inflammation are outlined. Unlike gout, there are no agents available that have been shown to decrease crystal load in CPPD-related joint disease. Recent novel insights into the pathogenesis of crystal-induced joint inflammation and subsequent joint degeneration are also discussed. The potential of colchicine as a prophylactic agent in managing recurrent attacks and the likely mechanisms of its effects on the NACHT, LRR and PYD domains-containing protein 3 (NALP-3) inflammasome of the innate immune system are highlighted. The use of agents that directly target the inflammasome, in particular drugs which inhibit the interleukin 1 pathway, in the treatment of severe, refractory pseudogout is also discussed. Finally, there is particular emphasis on the likely pathogenic role of CPPD crystal deposition in degenerative joint disease and the use of targeted anticrystal therapies as potential disease-modifying drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.